In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

The European Orthopedic Hip and Knee Implant Markets, 2003-2008

Executive Summary

The European orthopedic implants and trauma products market consists of hip, knee, shoulder, and small joint reconstruction and replacements; fracture fixation and bone growth stimulation; bone graft substitutes and growth factors; and bone cements segments. "European Markets for Orthopedic Implants and Trauma Products", a report published in October 2004 by Windhover/Medtech Insight, surveys and forecasts these markets in France, Germany, Italy, Spain, and the UK. Within these countries there is considerable potential for new and innovative technologies such as bone graft substitutes and the use of resorbable implants in trauma. However, medical-based evidence must show added value and improvement in a patient's quality of life before such innovations will be broadly accepted. Meeting health care regulatory authorities' compliance criteria while not burdening health care payers with dramatic increases in reimbursement budgets is viewed as a major driving factor within Europe.

You may also be interested in...



Denmark Leads The Way On Speeding Up Approvals For Drug/IVD Combination Trials

While an EU-level project is underway to address delays to drug trials that are conducted in combination with IVD performance studies, Denmark has streamlined its processes to address the issue at the national level.

First-In-Class Vorasidenib Among Bumper Crop Of New EU Filings

Twelve new drugs are now being reviewed for potential EU marketing approval, including Servier’s vorasidenib for IDH-mutant diffuse glioma, which the company says could become the first targeted therapy for the malignant and incurable brain tumor.

Australia Gears Up For More Action On Drug Shortages

The TGA has taken a series of actions to address supply chain issues, including on the regulatory front, but it says more remains to be done and is asking stakeholders for suggestions in a new online survey.

Topics

Related Companies

Related Deals

Latest Headlines
See All
UsernamePublicRestriction

Register

IV002249

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel